In particular, HER-2-negative tumor (p = 0.08), grade G1 (p < 0.001), achievement of BCS (p = 0.001), Ki-67 ≤ 14 % (p = 0.002), residual tumor ≤2 cm (p = 0.007), number of metastatic nodes ≤3 (p = 0.001), administration of adjuvant chemotherapy (p = 0.007), and stage I disease after surgery (p = 0.004) were associated with a better DFS. The gene discussed is ERBB2; the disease is neoplasm.